Get the Stockscreener App
26.55
7.89%
-2.275
Septerna Inc stock is traded at $26.55, with a volume of 84,235.
It is down -7.89% in the last 24 hours and up +8.64% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$28.82
Open:
$28.26
24h Volume:
84,235
Relative Volume:
0.29
Market Cap:
$1.19B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-12.32%
1M Performance:
+8.64%
6M Performance:
+83.99%
1Y Performance:
+347.73%
1-Day Range:
$25.98
$28.26
1-Week Range:
$25.98
$30.33
52-Week Range:
$4.66
$32.63
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
26.56 | 1.29B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.37 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.63 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.83 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.11 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.78 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Initiated | Truist | Buy |
| Nov-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
Insider Selling: Septerna (NASDAQ:SEPN) Insider Sells 70,453 Shares of Stock - MarketBeat
SEPN: SEP-631 advances to phase II in CSU after robust phase I results; SEP-479 enters clinical trials - TradingView
SEPN: SEP-631 and SEP-479 advance with strong data, phase 2 and 1 trials planned, and pipeline growth - TradingView
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN), Payoneer (PAYO) and Porch Group (PRCH) - The Globe and Mail
A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment - Sahm
Septerna (SEPN) Receives Overweight Rating and Target Price Hike by Wells Fargo | SEPN Stock News - GuruFocus
Wells Fargo & Company Increases Septerna (NASDAQ:SEPN) Price Target to $48.00 - MarketBeat
[144] Septerna, Inc. SEC Filing - Stock Titan
Septerna (NASDAQ:SEPN) Price Target Raised to $40.00 at HC Wainwright - MarketBeat
Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Septerna Advances SEP-631 After Positive Phase 1 Results - TipRanks
SEPN: SEP-631 showed strong Phase 1 efficacy and safety, advancing to Phase 2 for urticaria in 2026 - TradingView
Septerna reports positive Phase 1 SEP-631 data; plans Phase 2b CSU study in 2H 2026 - TradingView
Positive SEP-631 trial data drives Phase 2 plan at Septerna (NASDAQ: SEPN) - Stock Titan
Septerna’s SEP-631 shows positive Phase 1 trial results - Investing.com Australia
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy - Bitget
Septerna says SEP-631 well-tolerated with adverse event profile comparable to placebo - marketscreener.com
Septerna Says SEP-631 Well-Tolerated With Adverse Event Profile Comparable To Placebo - TradingView
Septerna pill blocked induced skin wheals at low doses in Phase 1 test - Stock Titan
Sentiment Watch: Is Septerna Inc part of any ETFBear Alert & Free Community Consensus Stock Picks - baoquankhu1.vn
Why Septerna (SEPN) Is Up 6.4% After Surging GPCR Pipeline-Driven Revenue GrowthAnd What's Next - simplywall.st
Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Septerna, Inc. (SEPN) Stock Analysis: Unleashing a 12,113% Revenue Growth Amidst Biotech Innovations - DirectorsTalk Interviews
Zacks Research Upgrades Septerna (NASDAQ:SEPN) to Hold - MarketBeat
Aug Breakouts: Does Septerna Inc have a sustainable dividendMarket Trend Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Septerna stock reaches all-time high at 31.39 USD By Investing.com - Investing.com Australia
Septerna (NASDAQ:SEPN) Reaches New 12-Month HighStill a Buy? - MarketBeat
SEP-631 Phase 1 Readout: The Catalyst Set To Drive Septerna In 2026 (NASDAQ:SEPN) - Seeking Alpha
Septerna stock reaches all-time high at 31.39 USD - Investing.com
Will Septerna Inc outperform the market in YEAR2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Septerna to Present at TD Cowen 46th Annual Health Care Conference - Bitget
Biotech Septerna to webcast TD Cowen health talk on March 3 - Stock Titan
SEPNSepterna, Inc. Latest Stock News & Market Updates - Stock Titan
Septerna president Bhatt sells $115,860 in shares By Investing.com - Investing.com South Africa
Septerna, Inc. (SEPN) Stock Analysis: A Biotech Powerhouse With A 25% Upside Potential - DirectorsTalk Interviews
Septerna president Bhatt sells $115,860 in shares - Investing.com Nigeria
Insider Selling: Septerna (NASDAQ:SEPN) COO Sells 4,000 Shares of Stock - MarketBeat
Will Septerna Inc. announce a stock split2025 Technical Overview & Accurate Intraday Trading Signals - mfd.ru
Septerna (NASDAQ:SEPN) Trading Down 5.9%Here's What Happened - MarketBeat
Will Septerna Inc. stock return to pre crisis levelsMarket Growth Report & Accurate Entry and Exit Point Alerts - mfd.ru
Insiders See US$934.3k Investment In Septerna Jump Last Week - 富途牛牛
Septerna (NASDAQ:SEPN) Hits New 1-Year HighWhat's Next? - MarketBeat
Septerna Inc stock hits all-time high at 30.51 USD By Investing.com - Investing.com Canada
Septerna Inc stock hits all-time high at 30.51 USD - Investing.com India
Septerna (NASDAQ:SEPN) Shares Up 9.4%Here's What Happened - MarketBeat
Risk Analysis: How volatile is Septerna Inc stockPortfolio Growth Summary & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Investment Recap: Is Septerna Inc forming a bullish divergenceNew Guidance & Consistent Growth Stock Picks - baoquankhu1.vn
Published on: 2026-02-21 01:46:34 - mfd.ru
Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Pioneer With 31.43% Upside Potential - DirectorsTalk Interviews
Loss Report: Does Septerna Inc have a sustainable dividendMarket Risk Analysis & Safe Entry Point Alerts - baoquankhu1.vn
How Early SEP-631 Data at AAAAI 2026 Will Impact Septerna (SEPN) Investors - simplywall.st
Septerna Inc Stock (SEPN) Financials Data
There is no financial data for Septerna Inc (SEPN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):